
We engineer technologies that support physicians in delivering high-quality care — complementing their clinical expertise through thoughtful innovation.
Our work in AI and intelligent systems is focused on helping improve detection, simplify workflows, and support more personalized care experiences.
Through close collaboration with the medical community, we are advancing the future of endoscopy and beyond — for clinicians, for patients, and for healthier communities worldwide.
Medtronic is the sole distributor, marketer and owner of GI Genius trademarks.
"We’ve released the first real-time AI-enhanced medical device, showing how healthcare professionals can get crucial advantage from AI technologies."1
Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care https://news.medtronic.com/2024-04-10-Medtronic-unveils-the-future-of-AI-in-GI-Genius-Summit-2024-reveals-innovations-and-collaborations-that-advance-endoscopic-care

The first real-time AI system in healthcare, GI Genius™ introduced real‑time colorectal polyp detection in 2019 and earned the FDA’s first De Novo clearance for an AI GI device in 2021. Since then, it has supported over 4 million patients worldwide.
Corley DA, Jensen CD, Marks AR Jr, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298‑1306. Available from: https://pubmed.ncbi.nlm.nih.gov/24693890/
GLOBOCAN. Estimated number of deaths in 2018 worldwide, both sexes, all ages. GLOBOCAN 2018 cancer data. Lyon (France): International Agency for Research on Cancer; 2018. Accessed Jan 2021. Summary in: Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‑424. Available from: https://pubmed.ncbi.nlm.nih.gov/30207593/
Wang P, Berzin TM, Glissen Brown JR, et al. Real‑time automatic detection system increases colonoscopic polyp and adenoma detection: a prospective randomised controlled study. Gut. 2019;68(10):1813‑1819. Available from: https://gut.bmj.com/content/68/10/1813.citation-tools
Repici A, Badalamenti M, Maselli R, et al. Efficacy of real‑time computer‑aided detection of colorectal neoplasia in a randomized trial. Gastroenterology. 2020;159(2):512‑520.e7. doi:10.1053/j.gastro.2020.04.062. Available from: https://pubmed.ncbi.nlm.nih.gov/32371116/
Medtronic plc. Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care. News release. 10 April 2024. Available from: https://news.medtronic.com/2024-04-10-Medtronic-unveils-the-future-of-AI-in-GI-Genius-Summit-2024-reveals-innovations-and-collaborations-that-advance-endoscopic-care
"The accuracy achieved by the hybrid AI-endoscopist team is higher than the accuracy of the endoscopist alone, or the AI alone."
In clinical trials, GI Genius™ cut missed polyp rates by up to
50%1,2,3
Winner of the Artificial Intelligence Innovation in
2023 AI Breakthrough Awards Program

Globally adopted by major health systems, including the U.S. Veterans Affairs, and honored on
Fortune’s “Change the World” list4
Zhao S, Wang S, Pan P, et al. Magnitude, risk factors, and factors associated with adenoma miss rate of tandem colonoscopy: a systematic review and meta‑analysis. Gastroenterology. 2019;156(6):1661‑1674.e11. doi:10.1053/j.gastro.2019.01.260. Available from: https://pubmed.ncbi.nlm.nih.gov/30738046/
Robertson DJ, Lieberman DA, Winawer SJ, Ahnen DJ, Baron JA, Schatzkin A, et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut. 2014;63(6):949‑956. doi:10.1136/gutjnl-2012-303796. Available from: https://gut.bmj.com/content/63/6/949 or https://pubmed.ncbi.nlm.nih.gov/23793224/
National Cancer Institute. Cancer Stat Facts: colon and rectum cancer. SEER Cancer Statistics Review. National Cancer Institute; [updated regularly]. Available from: https://seer.cancer.gov/statfacts/html/colorect.html
Fortune. Change the World list 2022. Fortune magazine; 2022. Company rankings available from: https://fortune.com/ranking/change-the-world/2022

A platform for bold thinkers and breakthrough technologies. Designed for developers, software innovators, and medtech startups, the Centre offers a unique opportunity to build, test, and refine real-time AI solutions for medical procedures.
Through access to our virtual sandbox environment and the GI Genius™ AI Access developer kit, innovators can accelerate time-to-market, validate their ideas in a realistic clinical context, and bring AI-powered tools closer to the point of care.
This is where clinical relevance meets technical ingenuity - and where the next generation of healthtech begins.
Join our Innovation Center and leverage the power of the GI Genius™ platform to bring your innovative AI medical product to market faster.